FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549	
-------------	------------	--

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SATO VICKI L						2. Issuer Name and Ticker or Trading Symbol Denali Therapeutics Inc. [DNLI]									all app	tionship of Reportir all applicable) Director Officer (give title		10% O	ner
(Last) (First) (Middle) C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD.						3. Date of Earliest Transaction (Month/Day/Year) 07/21/2021									below)		Other (s below)		specify
(Street) SOUTH FRANCI	- C Z	Λ 9	4080		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Form	or Joint/Group Filing (Check Applicable m filed by One Reporting Person m filed by More than One Reporting son			
(City)	(St		ip)	an Davine	4:	C		- 4 -		LDi		D		-:-!!	. 0	- d			
		lable	I - NO	on-Deriva	tive	Secui	ritie	S ACC	quirec	ı, Dis	sposed of	, or B	eneti	cially	Own	ea			
Date				2. Transacti Date (Month/Day	-	Executification if any	A. Deemed execution Date, any month/Day/Year)		3. Transaction Code (Instr. 8)			Acquired (A) o (D) (Instr. 3, 4		and 5) Securi Benefi		ties cially I Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) or (D)	Price		Transa	action(s) 3 and 4)			(11341.4)	
Common	Stock	07/21/2021				S ⁽¹⁾		400	D	\$64	.25 ⁽²⁾	134	4,097(3)		D				
Common	Stock			07/21/20	021				S ⁽¹⁾		866	D	\$65	.24 ⁽⁴⁾	4 ⁽⁴⁾ 133,231 ⁽³⁾ D				
Common Stock 07/21					021				S ⁽¹⁾		400	D	\$65	.78 ⁽⁵⁾	132,831 ⁽³⁾			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year)			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expira (Mont	ation D		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Der Sed (Ins	Price of ivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date		Amoun or Numbe of Shares	r					

Explanation of Responses:

- 1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- 2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$63.60 to \$64.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Includes 2.074 restricted stock units.
- 4. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$64.61 to \$65.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 5. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$65.63 to \$66.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Remarks:

/s/ Tyler Nielsen, by power of <u>attorney</u>

07/23/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.